Grant: Proof of Principle Program - Phase I
McGill University
$160,000.00
Benchmark proprietary pyridine- and thienopyrimidine-based bisphosphonates against the standard of care drug Zometa® in the treatment of multiple myeloma
FY 2013-14
Summary
The enzyme farnesyl pyrophosphate synthase (hFPPS) is responsible for the production of farnesyl pyrophosphate (FPP), a human metabolite that plays a major role in biochemical processes associated with cancer. Multiple myeloma is a cancer of the white blood cells that leads to bone lesions, osteoporosis and bone fracture. These symptoms occur in over 70% of patients and are the principle causes of disability and death in multiple myeloma patients. Current therapeutic strategies involve the use of hFPPS inhibitors, such as the drug Zometa, to minimize the bone-related adverse symptoms of this type of cancer. Zometa, as well as all other current drugs that inhibit hFPPS, bind almost exclusively to bone tissue and have exceptionally poor penetration into blood cells and soft tissues. Therefore, additional medications are required in order to treat the underlying cancer disease in multiple myeloma. We have identified novel inhibitors of hFPPS that exhibit better biopharmaceutical properties that those of Zometa. These compounds may be more useful in treating both the bone-related symptoms of multiple myeloma, as well as the primary cancer of the white blood cell. We will undertake several studies in animal models that closely mimic the human multiple myeloma cancer, in order to provide proof that our hFPPS inhibitors are valuable therapeutic agents for the treatment of multiple myeloma.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
293953
Name
Tsantrizos Youla S
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Not applicable / Specified
Prcname2
Proof of Principle
Projecttitle
Benchmark proprietary pyridine- and thienopyrimidine-based bisphosphonates against the standard of care drug Zometa® in the treatment of multiple myeloma
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Farnesyl Pyrophosphate Inhibitors; Multiple Myeloma
Abstract
The enzyme farnesyl pyrophosphate synthase (hFPPS) is responsible for the production of farnesyl pyrophosphate (FPP), a human metabolite that plays a major role in biochemical processes associated with cancer. Multiple myeloma is a cancer of the white blood cells that leads to bone lesions, osteoporosis and bone fracture. These symptoms occur in over 70% of patients and are the principle causes of disability and death in multiple myeloma patients. Current therapeutic strategies involve the use of hFPPS inhibitors, such as the drug Zometa, to minimize the bone-related adverse symptoms of this type of cancer. Zometa, as well as all other current drugs that inhibit hFPPS, bind almost exclusively to bone tissue and have exceptionally poor penetration into blood cells and soft tissues. Therefore, additional medications are required in order to treat the underlying cancer disease in multiple myeloma. We have identified novel inhibitors of hFPPS that exhibit better biopharmaceutical properties that those of Zometa. These compounds may be more useful in treating both the bone-related symptoms of multiple myeloma, as well as the primary cancer of the white blood cell. We will undertake several studies in animal models that closely mimic the human multiple myeloma cancer, in order to provide proof that our hFPPS inhibitors are valuable therapeutic agents for the treatment of multiple myeloma.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tsantrizos, Youla S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~